Safety and Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Mesoblast, Ltd.
ClinicalTrials.gov Identifier:
NCT01106417
First received: April 16, 2010
Last updated: March 11, 2014
Last verified: August 2012

April 16, 2010
March 11, 2014
June 2010
June 2014   (final data collection date for primary outcome measure)
Safety of NeoFuse [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
To determine the safety of NeoFuse using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and and immunology).
Same as current
Complete list of historical versions of study NCT01106417 on ClinicalTrials.gov Archive Site
Fusion success with NeoFuse [ Time Frame: 1 year ] [ Designated as safety issue: No ]
To evaluate the fusion success with NeoFuse compared to an active control using CT scans and x-ray of the involved cervical spine levels and assess the change in outcomes (NDI, SF-36, Zung Depression Questionnaire, and WPAI.
Same as current
Not Provided
Not Provided
 
Safety and Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion
Phase 2 Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With MasterGraft Matrix in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion With Anterior Cervical Plate Fixation

The purpose of this study is to evaluate the safety and preliminary efficacy of NeoFuse in subjects with a diagnosis of degenerative disc disease (DDD) at 2 or more adjacent cervical vertebral levels between C3-C4 to C7-T1. All subjects in this study will undergo 2 or 3 level anterior cervical discectomy and fusion with Anterior Cervical Plate Fixation.

This is a prospective, multicenter, randomized, single-blinded, controlled study evaluating safety and preliminary efficacy of immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse) combined with MasterGraft Matrix in a commercially available PEEK cervical Spacer compared to an active control in subjects undergoing 2 or 3 level anterior cervical discectomy and fusion with anterior cervical plate fixation.

After the screening and surgical visits, each subject will be evaluated clinically and radiographically within 3 days and 30 days after surgery, and at 3, 6, 12, and 24 months after surgery.

Subjects will be evaluated at the same time points for safety.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
  • Cervical Degenerative Disc Disease
  • Degenerative Spondylolisthesis
  • Spinal Stenosis
  • Procedure: NeoFuse
    Single Dose NeoFuse Surgical Implantation
    Other Names:
    • Anterior Cervical Discectomy and Fusion with NeoFuse
    • Cervical Spinal Fusion
    • Adult Stem Cells
  • Procedure: MasterGraft Granules
    Single Dose MaterGraft Granules Surgical Implantation
    Other Names:
    • Anterior Cervical Discectomy and Fusion with Granules
    • Cervical Spinal Fusion
    • Active Control
  • Experimental: NeoFuse
    Anterior Cervical Discectomy and Fusion with NeoFuse
    Intervention: Procedure: NeoFuse
  • Active Comparator: MasterGraft Granules
    Anterior Cervical Discectomy and Fusion with MasterGraft Granules
    Intervention: Procedure: MasterGraft Granules
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
12
June 2015
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or females between 18 and 70 years of age, inclusive.
  2. Has the ability to understand the requirements of the study, to provide written informed consent, and to comply with the study protocol.
  3. Has the ability to understand and provide written authorization for the use and disclosure of personal health information (PHI).
  4. Has a documented symptomatic diagnosis of DDD at C3-C4 to C7-T1.
  5. Has symptomatic radiculopathy and/or myelopathy correlating to radiographic findings of duration of 6 weeks or greater that had failed to respond to non-operative management
  6. Is a candidate for anterior cervical discectomy and fusion in two or three adjacent cervical interbody levels between C3-C4 to C7-T1
  7. Has a stable screening electrocardiogram (ECG), as determined by the investigator that would not preclude surgery.

Exclusion Criteria:

  1. Female subjects who are pregnant or nursing, or women planning to become pregnant during the first year (12 months) following surgery.
  2. Has a current or prior history within the last 3 years of neoplasm (excluding basal cell carcinoma) and/or any active neoplasm within the last 24 months, prior to screening.
  3. Has at the time of surgery a systemic or local infection at the site of proposed surgery.
  4. Has or is undergoing revision of a prior fusion surgery at any involved level.
  5. Requires ACDF at only one cervical interbody level or more than 3 adjacent cervical interbody levels.
  6. Requires ACDF without the use of an anterior cervical plating system.
  7. Has osteoporosis as defined by a DEXA T score of ≤ -3.0 or a history of fragility fractures or other significant bone disease contraindicating the use of spinal instrumentation.
  8. Has a documented medical history or radiographic evidence of a metabolic bone disease or other condition which would negatively impact the bone healing process.
  9. Has a positive screen for human immunodeficiency virus (HIV) antibodies.
  10. Has had treatment with any investigational therapy or device within 6 months of study surgery and/or plans to participate in any other allogeneic stem cell/progenitor cell therapy trial during the 2-year follow-up period.
  11. Has been a recipient of prior stem cell/progenitor cell therapy for spinal fusion surgery.
  12. Has 20% or greater anti-human leukocyte antigen (HLA) antibody titer and/or has antibody specificities to donor HLA antigens.
  13. Is transient or has been treated in the last 6 months before enrollment for alcohol and/or drug abuse in an inpatient substance abuse program.
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Australia
 
NCT01106417
MSB-CF001
Yes
Mesoblast, Ltd.
Mesoblast, Ltd.
Not Provided
Study Director: Roger Brown Mesoblast, Ltd.
Mesoblast, Ltd.
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP